Medical Information Only. Consult your healthcare provider before considering clinical trial enrollment.
Gastroesophageal Junction Adenocarcinoma: early-phase trial registry
24 of 41 indexed Gastroesophageal Junction Adenocarcinoma trials are currently recruiting, with more weight in Phase 1-2.
Corpus placement: #357 of 28,707 conditions by registered trial count.
41 US clinical trials · 24 currently recruiting · #357 of 28,707 conditions by registered trial count
Gastroesophageal Junction Adenocarcinoma: 41 US clinical trials tracked, 24 recruiting.
Gastroesophageal Junction Adenocarcinoma is the subject of 41 registered US clinical trials on ClinicalTrials.gov, 24 of them currently open to new participants. 5 are in Phase 3-4 (later-stage) and 32 in Phase 1-2 (earlier-stage). The most active sponsor is Seagen, a wholly owned subsidiary of Pfizer, running 3 of these trials.
Enrollment posture brief
Registry condition gastroesophageal-junction-adenocarcinoma
OPEN 24 | RECR 59% | LATE 5 | EARLY 32 | RANK #357 | SPON 3
Volume-matched condition peers
Nearest open-share peer: Stage IVB Prostate Cancer AJCC v8 (59% recruiting · 46 trials)
Gastroesophageal Junction Adenocarcinoma lists 24 open slots (59% of 41 indexed trials). Peers are matched on registered volume, not therapeutic-area browse lists. How peer matching works →
Key findings
What ClinicalTrials.gov does not surface for Gastroesophageal Junction Adenocarcinoma on its own pages , computed from the registry mirror as of 2026-08-08. Each line carries its own denominator so it can be quoted as it stands.
-
Gastroesophageal Junction Adenocarcinoma is recruiting above its size-band peers.
24 of 41 indexed trials (58.5%) are open to enrollment, against a 39.7% average across 762 conditions with 20-99 trials. The peer set uses the same ClinicalTrials.gov-derived counts as this page.
-
Sponsorship of Gastroesophageal Junction Adenocarcinoma trials is spread across many organizations.
Seagen, a wholly owned subsidiary of Pfizer accounts for 3 of 41 trials (7.3%). 31 distinct sponsors appear on at least one study for this condition label.
-
Typical Gastroesophageal Junction Adenocarcinoma enrolment sits around 146 participants.
Median target enrolment is 146 among the 41 trials that report a genuine target (sentinel values excluded). 16 of those (39%) plan for fewer than 100 participants.
-
Gastroesophageal Junction Adenocarcinoma research is mostly interventional.
38 interventional and 3 observational studies make up this index (92.7% interventional). Study type is sponsor-reported on ClinicalTrials.gov.
Open and recent trials
41 total, page 1 of 1
Sonesitatug Vedotin in Combination With Capecitabine With or Without Rilvegostomig in Participants With Advanced or Metastatic Gastric, Gastroesophageal Junction, or Esophageal Adenocarcinoma Expressing Claudin18.2
AstraZeneca
NCT07431281
Collecting Blood Samples From Patients With and Without Cancer to Evaluate Tests for Early Cancer Detection
Alliance for Clinical Trials in Oncology
NCT05334069
A Multicenter Cancer Biospecimen Collection Study
Cofactor Genomics
NCT04510129
A Study of Sigvotatug Vedotin in Advanced Solid Tumors
Seagen, a wholly owned subsidiary of Pfizer
NCT04389632
A Study of SGN-CEACAM5C in Adults With Advanced Solid Tumors
Seagen, a wholly owned subsidiary of Pfizer
NCT06131840
A Phase Ⅲ Study of Rilvegostomig in Combination With Fluoropyrimidine and Trastuzumab Deruxtecan as the First-line Treatment for HER2-positive Gastric Cancer
AstraZeneca
NCT06764875
Beamion BCGC-1: A Study to Find a Suitable Dose of Zongertinib Used Alone and in Combination With Other Treatments to Test Whether it Helps People With Different Types of HER2+ Cancer That Has Spread
Boehringer Ingelheim
NCT06324357
APL-101 Study of Subjects With NSCLC With c-Met EXON 14 Skip Mutations and c-Met Dysregulation Advanced Solid Tumors
Apollomics
NCT03175224
A Study to Investigate Tislelizumab Administered as Subcutaneous Injection Versus Intravenous Infusion Plus Chemotherapy in Patients With Unresectable or Metastatic Gastric or Gastroesophageal Junction Adenocarcinoma
BeOne Medicines
NCT07043400
A Study to Learn About the Study Medicine Called PF-08046876 in People With Advanced Solid Tumors
Pfizer
NCT07090499
A Study to Evaluate the Adverse Events, Efficacy, and Optimal Dose of Intravenous (IV) ABBV-400 in Combination With IV Fluorouracil, Leucovorin, and Budigalimab in Adult Participants With Locally Advanced Unresectable or Metastatic Gastric, Gastroesophageal Junction, or Esophageal Adenocarcinoma
AbbVie
NCT06628310
A Study of Disitamab Vedotin With Other Anticancer Drugs in Solid Tumors
Seagen, a wholly owned subsidiary of Pfizer
NCT06157892
Testing the Addition of Paclitaxel Administered Into the Abdominal Cavity Combined With Chemotherapy for Patients With Gastric Cancer Spread to the Abdominal Cavity
ECOG-ACRIN Cancer Research Group
NCT07001748
A Study of TRK-950 When Used in Combination With Ramucirumab and Paclitaxel in Patients With Gastric Cancer
Toray Industries
NCT06038578
Safety and Efficacy of NEO212 in Patients With Astrocytoma IDH-mutant, Glioblastoma IDH-wildtype or Brain Metastasis
Neonc Technologies
NCT06047379
A Study of KK2269 in Adult Participants With Solid Tumors
Kyowa Kirin Co.
NCT06266299
Evaluating the Effect of Itraconazole on Pathologic Complete Response Rates in Esophageal Cancer
Dallas VA Medical Center
NCT04018872
Safety of Combining Irinotecan With 5-FU, Leucovorin/Folinic Acid, Oxaliplatin, and Docetaxel Chemotherapies
University of Chicago
NCT04361708
Robotic Cytoreduction and Hyperthermic Intraperitoneal Chemotherapy for Treatment of Gastric Cancer With Limited Peritoneal Metastasis, ROBO-CHIP Study
Mayo Clinic
NCT05753306
Folfox+Irinotecan+Chemort In Esophageal Cancer
Massachusetts General Hospital
NCT04656041
Study of Suratadenoturev (OBP-301) in Combination With Pembrolizumab in Esophagogastric Adenocarcinoma
Weill Medical College of Cornell University
NCT06340711
NBTXR3, Chemotherapy, and Radiation Therapy for the Treatment of Esophageal Cancer
M.D. Anderson Cancer Center
NCT04615013
Aldesleukin With Nivolumab and Standard Chemotherapy for Treatment of Gastric Cancer With Peritoneal Metastasis
Mayo Clinic
NCT05802056
Tadalafil Effect + Chemotherapy in Resectable Gastric/GEJ Cancer
University of Arizona
NCT05709574
Phase I-II, FIH, TROP2 ADC, Advanced Unresectable/Metastatic Solid Tumors, Refractory to Standard Therapies (KL264-01)
Klus Pharma
NCT04152499
Study of Cabozantinib Alone or in Combination With Atezolizumab to Subjects With Locally Advanced or Metastatic Solid Tumors
Exelixis
NCT03170960
Bemarituzumab or Placebo Plus Chemotherapy in Gastric Cancers With Fibroblast Growth Factor Receptor 2b (FGFR2b) Overexpression
Amgen
NCT05052801
Bemarituzumab Plus Chemotherapy and Nivolumab Versus Chemotherapy and Nivolumab for FGFR2b Overexpressed Untreated Advanced Gastric and Gastroesophageal Junction Cancer.
Amgen
NCT05111626
Testing Immunotherapy (Atezolizumab) With or Without Chemotherapy in Locoregional MSI-H/dMMR Gastric and Gastroesophageal Junction (GEJ) Cancer
National Cancer Institute (NCI)
NCT05836584
First in Human Study of TORL-2-307-ADC in Participants With Advanced Cancer
TORL Biotherapeutics
NCT05156866
A Study of Evorpacept (ALX148) in Patients With Advanced HER2+ Gastric Cancer (ASPEN-06)
ALX Oncology
NCT05002127
First in Human Study of TORL-2-307-MAB in Participants With Advanced Cancer
TORL Biotherapeutics
NCT05159440
Durvalumab, an Anti-PDLI Antibody, and Tremelimumab, an Anti-CTLA4 Antibody, and Chemoradiation Before Surgery for Esophageal Cancer
Memorial Sloan Kettering Cancer Center
NCT02962063
Telehealth for the Self-Management of Dietary Quality of Life in Patients After Stomach Cancer Surgery
City of Hope Medical Center
NCT05203627
Study of Sequential Systemic Therapy + Intraperitoneal Paclitaxel in Gastric/GEJ Peritoneal Carcinomatosis
University of California, Irvine
NCT04762953
A Study of Minimally Invasive Proximal Gastrectomy Versus Minimally Invasive Total Gastrectomy for Gastric and Gastroesophageal Junction Cancers
Memorial Sloan Kettering Cancer Center
NCT06243757
A Phase 2 Study of Ramucirumab (LY3009806) in Participants With Gastric or Gastroesophageal Junction (GEJ) Cancer
Eli Lilly and Company
NCT02443883
Study of Modified Docetaxel, Cisplatin, and Fluorouracil (mDCF) in Unresectable or Metastatic Gastric and Gastroesophageal Junction Adenocarcinoma
Memorial Sloan Kettering Cancer Center
NCT00515411
A Study of Ramucirumab (LY3009806) Plus MEDI4736 in Participants With Advanced Gastrointestinal or Thoracic Malignancies
Eli Lilly and Company
NCT02572687
Tucatinib, Trastuzumab, Ramucirumab, and Paclitaxel Versus Paclitaxel and Ramucirumab in Previously Treated HER2+ Gastroesophageal Cancer
Seagen
NCT04499924
Pembrolizumab in Treating Patients With Metastatic or Unresectable Gastroesophageal Adenocarcinoma
M.D. Anderson Cancer Center
NCT03395847
Phase Distribution
| Phase | Trial count |
|---|---|
| Phase 1 | 16 |
| Phase 2 | 16 |
| Phase 3 | 5 |
Top Sponsors
Named interventions
Most-linked intervention names on Gastroesophageal Junction Adenocarcinoma records (sponsor-reported on ClinicalTrials.gov). Counts are trial links, not unique products.
US sites by state
Facility locations filed on Gastroesophageal Junction Adenocarcinoma trials. A trial with sites in several states counts in each.
Source: ClinicalTrials.gov, National Library of Medicine. Data is informational only.
Related
What to do with this Gastroesophageal Junction Adenocarcinoma page
41 registered trials, 24 currently recruiting, is a starting point for a conversation, not a diagnosis or a recommendation.
- 24 Gastroesophageal Junction Adenocarcinoma trials are currently recruiting, check eligibility criteria before contacting a site. Browse recruiting trials
- Seagen, a wholly owned subsidiary of Pfizer sponsors the most Gastroesophageal Junction Adenocarcinoma trials on record, review their full trial history before evaluating a specific study. See Seagen, a wholly owned subsidiary of Pfizer's trials
- Bring the specific trial ID (NCT number) to your own doctor before enrolling, this page is a directory, not medical guidance. Read the trial-finding guide
Trial and recruiting counts reflect ClinicalTrials.gov registry status as of the data vintage above; individual trial eligibility and enrollment status can change.
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This Gastroesophageal Junction Adenocarcinoma condition card totals 41 registered trials; most-linked intervention Ramucirumab; top US site state California. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.